For research use only. Not for therapeutic Use.
Levonebivolol, also known as R 67145, is an enantiomer of Nebivolol which is a β1 receptor blocker with nitric oxide-potentiating vasodilatory effect used in treatment of hypertension and, in Europe, also for left ventricular failure. It is highly cardioselective under certain circumstances.
| Catalog Number | R007190 |
| CAS Number | 118457-16-2 |
| Synonyms | (αS,α’S,2R,2’S)-α,α’-[Iminobis(methylene)]bis[6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol]; [2S-[2R*[R*[R*(S*)]]]]-α,α’-[Iminobis(methylene)]bis[6-fluoro-3,4-dihydro-?2H-1-benzopyran-2-methanol; Levonebivolol; R 67145; l-Nebivolol |
| Molecular Formula | C₂₂H₂₅F₂NO₄ |
| Purity | ≥95% |
| Storage | -20°C |
| Reference | </br>1:Protective effects of Nebivolol against interleukin-1β (IL-1β)-induced type II collagen destruction mediated by matrix metalloproteinase-13 (MMP-13). Li Z, Liu B, Zhao D, Wang B, Liu Y, Zhang Y, Tian F, Li B.Cell Stress Chaperones. 2017 May 17. doi: 10.1007/s12192-017-0805-x. [Epub ahead of print] PMID: 28512729 </br>2:Rationale for nebivolol/valsartan combination for hypertension: review of preclinical and clinical data. Giles TD, Cockcroft JR, Pitt B, Jakate A, Wright HM.J Hypertens. 2017 May 15. doi: 10.1097/HJH.0000000000001412. [Epub ahead of print] PMID: 28509722 </br>3:Antihypertensive drugs aliskiren, nebivolol, and olmesartan reduce hypertension by reducing endothelial microparticle and regulating angiogenesis. Jain M, Bhosale V, Tripathi D, Singh H, Pal N, Hanif K, Jagavelu K.J Cardiovasc Pharmacol. 2017 May 9. doi: 10.1097/FJC.0000000000000503. [Epub ahead of print] PMID: 28498232 </br>4:Investigation of a Potential Pharmacokinetic Interaction Between Nebivolol and Fluvoxamine in Healthy Volunteers. Gheldiu AM, Vlase L, Popa A, Briciu C, Muntean D, Bocsan C, Buzoianu A, Achim M, Tomuta I, Todor I, Neag M.J Pharm Pharm Sci. 2017;20:68-80. doi: 10.18433/J3B61H. PMID: 28459657 Free Article</br>5:Lichenoid type cutaneous hyperpigmentation induced by nebivolol. Aslan AN, Güney MC, Akçay M, Keleş T, Bozkurt E.Turk Kardiyol Dern Ars. 2017 Apr;45(3):268-270. doi: 10.5543/tkda.2016.02151. PMID: 28429695 Free Article</br>6:Correction: Nebivolol, a β1-adrenergic blocker, protects from peritoneal membrane damage induced during peritoneal dialysis. Liappas G, González-Mateo G, Aguirre AR, Abensur H, Albar-Vizcaino P, Parra EG, Sandoval P, Ramírez LG, Del Peso G, Acedo JM, Bajo MA, Selgas R, Sánchez Tomero JA, López-Cabrera M, Aguilera A.Oncotarget. 2017 Apr 4;8(14):24045. doi: 10.18632/oncotarget.16782. No abstract available. PMID: 28423612 Free PMC Article</br>7:Studies directed toward the exploitation of vicinal diols in the synthesis of (+)-nebivolol intermediates. Devi R, Das SK.Beilstein J Org Chem. 2017 Mar 21;13:571-578. doi: 10.3762/bjoc.13.56. eCollection 2017. PMID: 28405237 Free PMC Article</br>8:Nebivolol/valsartan: Fixed-dose combination for treatment of hypertension. Paton DM.Drugs Today (Barc). 2017 Jan;53(1):19-26. doi: 10.1358/dot.2017.53.1.2560078. PMID: 28387384 </br>9:Role of nebivolol in the control and management of central aortic blood pressure in hypertensive patients. Borghi C, Acelajado MC, Gupta Y, Jain S.J Hum Hypertens. 2017 Apr 6. doi: 10.1038/jhh.2017.26. [Epub ahead of print] Review. PMID: 28382958 </br>10:Photolytic degradation of the β-blocker nebivolol in aqueous solution. Salma A, Lutze HV, Schmidt TC, Tuerk J.Water Res. 2017 Jun 1;116:211-219. doi: 10.1016/j.watres.2017.03.029. Epub 2017 Mar 13. PMID: 28340419 |
